ThirdLaw Molecular pioneers revolutionary SpiroligomerN molecules for safer, more targeted, effective disease treatment.
ThirdLaw Molecular has raised $1.5M in total funding. The most recent round was Pre-Seed. The last funding was announced in February 2025.
ThirdLaw Molecular's investors include SmartGateVC, Defense Threat Reduction Agency (DTRA), Bowman's Tower Venture Partners.
ThirdLaw Molecular is headquartered in Blue Bell, United States.
ThirdLaw Molecular pioneers revolutionary SpiroligomerN molecules for safer, more targeted, effective disease treatment.
ThirdLaw Molecular is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ThirdLaw Molecular — Funding & Investors." VCBacked, February 13, 2025, https://www.vcbacked.co/company/thirdlaw-molecular. Accessed August 1, 2026.
VCBacked. (2025). ThirdLaw Molecular — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/thirdlaw-molecular
{{cite web |title=ThirdLaw Molecular — Funding & Investors |url=https://www.vcbacked.co/company/thirdlaw-molecular |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated